Eupraxia Pharmaceuticals
EPRX
27 hedge funds and large institutions have $75.3M invested in Eupraxia Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
591% more capital invested
Capital invested by funds: $10.9M → $75.3M (+$64.4M)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
93% more funds holding
Funds holding: 14 → 27 (+13)
30.15% more ownership
Funds ownership: 5.48% → 35.63% (+30%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGC
Beutel, Goodman & Co
Toronto,
Ontario, Canada
|
+$22.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.35M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.35M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.53M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$108K |
| 2 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$76.7K |
| 3 |
QC
Quadrature Capital
London,
United Kingdom
|
-$61.4K |
| 4 |
JP Morgan Chase
New York
|
-$12.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
National Bank of Canada
Montreal,
Quebec, Canada
| $5.03K | +$827 | +152 | +21% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $53 | +$49 | +9 | New |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$108K | -18,236 | Closed |
|
|
QC
29
Quadrature Capital
London,
United Kingdom
| – | -$61.4K | -10,700 | Closed |
|
EPRX Hedge Fund Activity: Q3 2025 in Review
27 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q3 2025, worth a combined $75.3M — up 591% from $10.9M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new EPRX positions and 2 closed out — a net gain of 13 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Beutel, Goodman & Co, opening a new position worth an estimated $22.1M. The largest seller was Citadel Advisors, exiting entirely with an estimated $108K sold.
- 27 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q3 2025, up from 14 in Q2 2025.
- Funds reported $75.3M of Eupraxia Pharmaceuticals stock for Q3 2025, up 591% quarter-over-quarter.
- 15 funds opened new Eupraxia Pharmaceuticals positions in Q3 2025 and 2 closed out, a net change of +13 holders.
- The largest Eupraxia Pharmaceuticals buyer in Q3 2025 was Beutel, Goodman & Co, an estimated $22.1M added.
- The largest Eupraxia Pharmaceuticals seller in Q3 2025 was Citadel Advisors, an estimated $108K sold.
Based on aggregated 13F filings for Q3 2025.